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ANNEXURE
INTRODUCTION
Jaundice is the commonest abnormal finding in the first week of 
life. The clinical jaundice will manifest in neonates at a serum bilirubin 
level  above  5.0  to  7.0  mg/dL  (86  –  119  micromoles/L) 1.  Chemical 
hyperbilirubinemia, which is defined as serum total bilirubin level of 2.0 
mg/dL  (34micromoles/L)  or  more,  is  virtually  universal  in  newborns 
during first week of life 1.
Between 25 – 50 % of all term newborns and a higher percentage 
of premature infants develop clinical jaundice. Also 6.1 % of well term 
newborns have a maximal serum bilirubin level > 12.9mg/dL. A serum 
bilirubin level of > 15mg/dL is found in 3 % of normal term babies 2. As 
the intensity of jaundice increases, there is cephalocaudal progression of 
yellow discolouration of skin.
Hyperbilirubinemia can cause bilirubin encephalopathy and severe 
sequelae.  So  it  is  imperative  that  pathological  hyperbilirubinemia  is 
picked up early  and vigorous  treatment  is  started.  When the  newborn 
stays at the hospital for a 72-hour post-delivery period, it is possible to 
observe the peaking of the physiological jaundice, thus allowing medical 
intervention, if necessary. However, in cases of early discharge from the 
hospital, the newborns may be subjected to re-admission for phototherapy 
treatment  because of  high levels  of  unconjugated bilirubin  3.  Such re-
admissions, besides involving extra expenses for both the family and the 
institution and also exposing a probably healthy newborn to the hospital 
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environment, brings emotional problems and risks to breast-feeding, and 
is one of the causes of early weaning 4. 
In  the  Institute  of  Obstetrics  and  Gynaecology  there  are  1800 
deliveries conducted every month and most babies were discharged in 48 
to 72 hours unless they are delivered by caesarean section or there are 
some maternal  or  newborn complications.  5-10% babies  delivered  are 
admitted  in  the  newborn  unit  for  neonatal  hyperbilirubinemia,  out  of 
which the major number of cases are due to ABO incompatibility. So it is 
worth  screening  these  babies  who  are  at  risk  of  developing  ABO 
incompatibility. With this idea in mind this study is embarked upon.
BILIRUBIN METABOLISM
Bilirubin  is  a  yellow  breakdown product  of  normal  heme 
catabolism.  Bilirubin  formed  in  utero  by  the  fetus  is  cleared  by  the 
placenta. 75% of bilirubin is derived from the breakdown of hemoglobin 
and 25% from non hemoglobin sources like myoglobin and cytochrome.
Bilirubin is carried bound to albumin to the liver. In liver bilirubin 
is transferred across the cell membrane into the hepatocyte where it is 
bound  principally  to  ligandin  5,  6,  conjugated  with  two  glucuronide 
molecules  and  excreted  through  the  bile  into  the  intestine7.  In  the 
presence  of  normal  gut  flora,  the  conjugated  bilirubin  is  metabolized 
further to stercobilins and excreted in the stool. In the absence of gut flora 
and with slow intestinal motility, the conjugated bilirubin remains in the 
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intestinal  lumen,  where  a  mucosal  enzyme  (beta-glucuronidase)  can 
cleave off the glucuronide molecules, leaving unconjugated bilirubin to 
be reabsorbed (the enterohepatic circulation of bilirubin). 
BILIRUBIN ALBUMIN BINDING
Unconjugated bilirubin is  bound tightly to albumin at a  primary 
(high-affinity)  binding  site  as  well  as  a  secondary  (low-affinity)  site. 
Because binding affinity at the primary binding site is 107 to 108 L/mol, 
the concentration of free or unbound bilirubin in plasma is very low, even 
in  the  presence  of  significant  hyperbilirubinemia  8.  Under  normal 
circumstances 99.9% of the unconjugated bilirubin is bound to albumin. 
Free bilirubin is therefore present only in nanomole quantities. At lower 
pH bilirubin  combines  with  H+  and  form bilirubin-H2 which  is  water 
insoluble  and forms  complexes  with  phospholipids  in  cell  membranes 
leading to the neuronal damage of kernicterus.
FACTORS AFFECTING BILIRUBIN BINDING TO ALBUMIN
Acid pH decreases the binding of bilirubin with albumin. Drugs 
like sulfonamides, moxalactam, fusidic acid, radiographic contrast media, 
aspirin and rapid infusion of ampicillin displaces bilirubin from albumin 
binding  sites  1.  Long  chain  free  fatty  acids  decrease  the  binding  of 
bilirubin to albumin.
MEASUREMENT OF BILIRUBIN LEVELS
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Although  bilirubin  estimation  is  one  of  the  most  commonly 
performed  laboratory  measurements  in  the  newborn,  its  measurement 
remains remarkably inaccurate 9, 10. Various methods can be used for the 
estimation of bilirubin.
Biochemical:  Laboratory  estimation  of  total  and  conjugated 
bilirubin based on Vanden Bergh reaction remains the gold standard for 
bilirubin estimation. Total  and direct  bilirubin levels  can be measured 
from the  blood,  but  indirect  bilirubin is  calculated  from the  total  and 
direct bilirubin. Bilirubin is broken down by light when kept outside. But 
under  the  usual  clinical  conditions,  there  is  no  measurable  effect  of 
ambient light on serum bilirubin levels for at least 8 hours 11.
Bilimeter is based on spectro-photometry and estimates total serum 
bilirubin.  It  is  useful  in  neonates,  as  bilirubin  is  predominantly 
unconjugated. 
Transcutaneous bilirubinometer is non invasive and based on the 
principle  of  multi-wavelength  spectral  reflectance  from  the  bilirubin 
staining in the skin. It could be used not only as a screening device but 
also as a reliable substitute for total serum bilirubin estimation 12. 
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MECHANISM OF HYPERBILIRUBINEMIA IN NEWBORN
Several  physiological  handicaps lead to increased frequency and 
severity of jaundice among newborn babies. Physiological polycythemia 
and shorter  lifespan of  fetal  red blood cells  (90 days vs.  120 days  in 
adults) results in release of 0.15g/kg of hemoglobin every day as 1ml/kg 
of blood hemolyses every day. One gram of hemoglobin yields about 34 
mg  of  bilirubin.  Additional  1mg/kg  of  bilirubin  is  formed  from  non 
hemoglobin  sources  viz.  myoglobin,  cytochromes  and  catalases  thus 
resulting in net daily load of about 20mg of bilirubin to the liver in a 
healthy  term  infant.  Bilirubin  production  decreases  with  increasing 
postnatal age but is still about twice the adult rate by age 2 weeks 13.
Circulating bilirubin is bound to plasma albumin. It is believed that 
the neurotoxicity associated with hyperbilirubinemia is primarily a result 
of unbound or ‘free’ bilirubin. So the amount of albumin available for 
binding is important. The full term newborn infant has a significantly low 
level  of  plasma  albumin  compared  to  that  for  an  adult  and 
correspondingly less bilirubin binding sites. Adult levels are reached only 
by 5 months. Various drugs compete with bilirubin for binding site in 
albumin.  Acid pH and free fatty  acid decrease binding of  bilirubin to 
albumin.
Hepatic uptake, conjugation and excretion of bilirubin are limited 
due  to  transient  deficiency  of  Y  and  Z-acceptor  proteins  and  UDP 
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glucuronyl transferase enzyme in newborn babies especially those born 
prematurely. In the first 10 days after birth, UDP glucuronyl transferase 
enzyme activity in full-term and premature neonates is usually less than 
1%  of  the  adult  values  14,  15.  Thereafter,  its  activity  increases  at  an 
exponential rate, reaching adult values by 6 to 14 weeks of age 15. 
Infants  have  fewer  bacteria  in  their  small  and  large  bowel  and 
greater activity of the deconjugating enzyme beta glucuronidase 16. As a 
result  conjugated bilirubin which is not reabsorbed is not converted to 
urobilinogen  but  is  hydrolyzed  to  unconjugated  bilirubin,  which  is 
reabsorbed, thus increasing the bilirubin load on an already stressed liver. 
Enterohepatic  circulation  of  bilirubin  is  a  significant  contributor  to 
physiologic jaundice 17. In the first few days after birth, caloric intake is 
low, which contributes to an increase in the enterohepatic circulation 18, 19. 
Thus  increased  production,  reduced  hepatic  clearance  and  enhanced 
entero-hepatic  circulation  of  bilirubin  contributes  to  the  increased 
prevalence of jaundice among newborn babies.
Multiple  studies  over  the  last  25  years  have  found  a  strong 
association  between  breast-feeding  and  an  increased  incidence  of 
neonatal  hyperbilirubinemia  20.  Although  occasional  studies  have  not 
proved  this,21,22 a  pooled  analysis  of  12  studies  of  more  than  8,000 
newborns showed that breast-fed infants were three times more likely to 
develop total serum bilirubin levels of 12 mg/dL (205 µmol/L) or higher 
and six times more likely to develop levels of 15 mg/dL (257 µmol/L) or 
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higher  than formula-fed  infants  23 .  Ninety  percent  or  more of  infants 
readmitted  to  hospital  in  the  first  2  weeks  of  life  because  of  severe 
hyperbilirubinemia  are  fully  or  partially  breast-fed  24,  25,  26.  A  similar 
results were obtained from a study conducted in North California also 27.
The causes of hyperbilirubinemia in newborn period are shown in 
the table below.
HEMOLYTIC DISORDERS
Rh and ABO incompatibility
Hereditary spherocytosis
G 6 PD deficiency
Alpha thalassemia
Acquired hemolysis due to drugs MIXED  OBSTRUCTIVE 
DISORDERS
EXTRAVASCULAR BLOOD Sepsis
Petechiae, hematomas Intra uterine infections
Pulmonary/cerebral/occult hemorrhage. RDS
POLYCYTHEMIA Asphyxia
Feto maternal or feto-fetal transfusion IDM
Delayed clamping of umbilical cord INCREASED 
ENTEROHEPATIC 
CIRCULATION
METABOLIC CAUSES Intestinal atresia
Galactosemia Hirschprungs disease
Criggler – Najar syndrome Meconium ileus
Gilbert’s disease Fasting hypoperistalsis
Hypothyroidism Drug induced paralytic ileus
Tyrosinosis Swallowed maternal blood
IDM
Prematurity
Breast milk jaundice
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HEMOLYTIC JAUNDICE
Hemolytic  disease  in  newborn  period  as  a  consequence  of 
alloimmunisation  of  the  mother  is  caused  by  the  passage  of  fetal 
erythrocytes into the maternal  circulation,  in  which they  stimulate  the 
production of antibodies. Antibodies of the IgG class return to the fetal 
circulation, attach to antigenic sites on the surface of the erythrocyte, and 
cause  its  rapid  removal  by  the  fetal  reticuloendothelial  system.  The 
incidence and clinical manifestations of alloimmunisation depend on the 
type of blood group incompatibility between the mother and fetus 28, 29, 30. 
The  common  causes  of  hemolytic  jaundice  in  newborn  include  Rh 
hemolytic disease, ABO incompatibility, G-6-PD deficiency and minor 
blood group incompatibility.
The catabolism of erythrocytes results in the equimolar production 
of bilirubin and carboxyhemoglobin 31. A rapid increase in the degree of 
hyperbilirubinemia  is  a  cardinal  sign  of  erythrocyte  destruction.  The 
measurement  of  blood  carboxyhemoglobin  or  the  rate  of  carbon 
monoxide excretion 32 correlates with the degree of hemolysis 33, 34.
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RH HEMOLYTIC DISEASE
The incidence of Rh incompatibility in a population depends, in 
large part, on the prevalence of the Rh-negative antigens. The prevalence 
of the Rh-negative genotype ranges from approximately zero in Japanese, 
Chinese, and North American Indian populations to 5.5% among African-
Americans and 15% among American Caucasians 35, 36. Among Caucasian 
women,  it  has  been  estimated  that  in  approximately  9%  of  all 
pregnancies, an Rh-negative woman carries an Rh-positive fetus. In 6% 
of pregnancies at risk, alloimmunisation of the mother occurs if there is 
no immunoprophylaxis 1. 
The severity of Rh hemolytic disease varies greatly from infant to 
infant. It is estimated that, without antenatal diagnosis and treatment, the 
perinatal mortality in this disease would be approximately 17.5%, with 
stillbirths accounting for about 14% of deaths 30. The degree of hemolytic 
disease tends to be more severe in subsequent pregnancies than in the 
initial one in which sensitisation had occurred. 
Rh immunisation tends to occur  more frequently  in pregnancies 
that  have  been  complicated  by  toxemia,  cesarean  section,  or  manual 
removal of the placenta, because transplacental hemorrhages occur with 
greater frequency and in greater volume under these circumstances. It is 
estimated  that  1%  of  Rh-negative  women  develop  antibodies  as  a 
consequence of these transplacental hemorrhages before the delivery of 
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their first  child.  An additional  7.5% manifest  evidence of sensitisation 
within 6 months of  the delivery of  their  first  child,  and another  7.5% 
show no evidence of immunisation 6 months after delivery but develop 
antibodies  during  their  next  pregnancy  if  their  fetus  is  Rh-positive, 
presumably as a consequence of a sensitisation during the first pregnancy.
ABO HEMOLYTIC DISEASE
Feto maternal ABO incompatibilities occur in about 20 – 25 % of 
pregnancies but  severe hemolytic disease develop in only one in ten of 
such offspring. In ABO hemolytic disease of the newborn (also known as 
ABO HDN) maternal IgG antibodies with specificity for the ABO blood 
group system pass through the  placenta to the  fetal circulation where 
they can cause hemolysis of fetal red blood cells which can lead to fetal 
anemia and hemolytic disease.
Anti-A and anti-B antibodies are found in the IgA, IgM, and IgG 
fractions of plasma. Only the IgG antibodies cross the placenta and are 
responsible  for  the  production  of  disease.  These  naturally  occurring 
antibodies  result  from  continuous  immune  stimulation  by  A  and  B 
substances that  exist  in  foods  and gram-negative  bacteria.  Anti-A and 
anti-B  titers  are  low  or  absent  in  most  pregnancies  and  it  is  not 
understood why some women develop high anti-A or anti-B titers. They 
may be the result of repeated, asymptomatic bacterial infections. 
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Fewer A or B antigenic sites are present on the erythrocytes of the 
newborn,  which is responsible for the weakly reactive Coombs test  in 
infants  with  ABO  hemolytic  disease. Significant  jaundice  in  Direct 
Antiglobulin Test -negative neonates with ABO incompatibility (mother 
blood group O, infant A or B) is still often attributed to isoimmunisation. 
The  sparse  distribution  of  A  and  B  sites  on  the  erythrocytes  of  the 
newborn also explains why the erythrocyte life span in ABO hemolytic 
disease is only slightly shortened.
Before birth, the chief danger of excess erythrocyte destruction is 
profound anemia. After birth, the infant is primarily at risk from the toxic 
products of erythrocyte breakdown, such as bilirubin. In utero, the infant 
responds to the increased breakdown of cells by increasing the rate of 
erythrocyte production. This accelerated demand for erythrocytes results 
in active erythropoiesis in non-marrow sites such as the liver, spleen, and 
lung. A major portion of the hepatosplenomegaly observed in infants with 
hemolytic disease is a result of this extramedullary erythropoiesis.
BILIRUBIN TOXICITY
The  effects  of  bilirubin  toxicity  are  often  devastating  and 
irreversible.  Acute bilirubin encephalopathy is classically seen in term 
infants dying of Rh hemolytic disease with high (>20 mg/dL) bilirubin 
levels who had kernicterus on autopsy. The AAP recommends 37 that the 
term  acute  bilirubin  encephalopathy  is  used  to  describe  the  acute 
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manifestations of bilirubin toxicity seen in the first weeks after birth and 
that  the  term  kernicterus  be  reserved  for  the  chronic  and  permanent 
clinical sequelae of bilirubin toxicity. Johnson and associates suggested 
the use of the term bilirubin-induced neurologic dysfunction (BIND) to 
describe the changes associated with acute bilirubin encephalopathy; they 
also proposed a scoring system to quantify  the severity of the clinical 
manifestations38. 
The  clinical  presentation  of  bilirubin  encephalopathy  can  be 
divided into three phases.
1. In the early phase, the infant becomes lethargic and hypotonic, and 
sucks poorly. 
2. The  intermediate  phase  is  characterized  by  moderate  stupor, 
irritability, and hypertonia. The infant may develop a fever and a 
high-pitched  cry  39,  which  might  alternate  with  drowsiness  and 
hypertonia. 
3. The  advanced  phase  is  characterized  by  pronounced  retrocollis-
opisthotonus, shrill cry, refusal to feeds, apnea, fever, deep stupor 
to coma, and sometimes seizures and death 39, 40, 41. 
Subsequently,  usually  after  1  week,  hypertonia  subsides  and  is 
replaced by hypotonia.  In  the  first  year,  infants  typically  feed  poorly, 
develop a high-pitched cry, and are hypotonic, but have increased deep 
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tendon reflexes, a persistent tonic neck reflex, and motor delay 42. There 
is  a  delay  in  acquisition  of  motor  skills,  although most  children  walk 
alone by 5 years of age. The other typical features of chronic bilirubin 
encephalopathy usually are not apparent before 1 year of age and often 
not for several years 39. These children generally are hypotonic at rest for 
the first 6 or 7 years. By the time they reach their teens, hypertonia will 
replaced hypotonia 43.
Chronic bilirubin encephalopathy constitutes a tetrad consisting of 
extra pyramidal  disturbances,  auditory abnormalities,  gaze palsies,  and 
dental dysplasia 43. 
The term “Kernicterus” refers to the neurologic consequences of 
the deposition of unconjugated bilirubin in brain tissue. Full-term infants 
who die of kernicterus demonstrate bilirubin staining in a characteristic 
distribution. The regions most commonly affected are the basal ganglia, 
particularly  the  sub  thalamic  nucleus  and  the  globus  pallidus,  the 
hippocampus, the geniculate bodies, various brainstem nuclei, including 
the  inferior  colliculus,  oculomotor,  vestibular,  cochlear,  and  inferior 
olivary  nuclei,  and the cerebellum,  especially  the  dentate  nucleus  and 
vermis  44,  45.  Subsequent damage and scarring of the basal ganglia and 
brain-stem nuclei may occur 46. 
The exact bilirubin concentration associated with kernicterus in a 
healthy term infant  is  unpredictable.  Toxicity levels may vary among 
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ethnic  groups,  with maturation  of  an infant,  and with the presence of 
hemolytic  disease.  Although  the  risk  of  bilirubin  toxicity  is  probably 
negligible in a healthy term newborn without hemolysis, the physician 
should become concerned if the bilirubin level is above 25 mg per dL 
(428 µmol per L).  In the term newborn with hemolysis, a bilirubin level 
above 20 mg per dL (342 µmol per L) is a concern. 
SCREENING OF BABIES FOR ALLO IMMUNISATION
NEED FOR SCREENING
In  the  era  of  early  discharge  of  newborns  from  the  hospital, 
newborns  with  ABO incompatibility  are  especially  at  greater  risk  for 
developing  a  significant  hyperbilirubinemia  after  discharge  and  a 
considerable  percentage  of  these  could  present  with  isoimmunisation 
(ABO).  Early  prediction  of  a  likelihood  of  pathological 
hyperbilirubinemia  could  decrease  the  need  for  exchange  transfusion, 
which also can cause some complications.  The use of some screening 
tests have significantly decreased the incidence of exchange transfusion 
in developed countries.
ANTENATAL SCREENING FOR ALLO IMMUNISATION
All pregnant women should be tested for ABO and Rh (D) typing 
and  undergo  a  serum screen  for  unusual  isoimmune  antibodies  37.  In 
infants of group O or Rh-positive mothers,  the AAP recommends that 
routine testing for blood type and Coombs test is optional provided there 
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is  appropriate  surveillance  and  risk  assessment  before  discharge  and 
follow up so that significantly jaundiced infants are not missed.
ANTIBODY TITERS
Serial  antibody  titers  are  the  mainstay  of  maternal  assessment. 
After  it  is  determined  that  there  is  maternal  sensitisation  and  the 
possibility  of  fetal  antigen  positivity,  additional  antibody  titer 
determinations  should  be  performed  as  the  pregnancy  progresses.  A 
second  maternal  antibody  titer  is  performed  at  18  to  20  weeks  of 
gestation and then repeated monthly for the rest of the pregnancy. Rarely 
does significant hemolytic disease in the fetus occur before 20 weeks of 
gestation. Those patients who have a positive antibody screen for the Dd 
antigen, or for one of the atypical antigens that are capable of causing 
significant hemolytic disease of the newborn, need close follow up.
Severe hemolytic disease of the newborn rarely occurs when the 
Coombs titer is less than 1:16. Therefore, patients whose antibody titers 
are below this level can be managed expectantly and delivered at term 
with little change in routine obstetric care.
Patients  whose  antibody  titer  in  the  current  or  any  previous 
pregnancy has exceeded 1:16 and who are carrying a potentially antigen-
positive fetus must be considered at risk for severe hemolytic disease of 
the newborn.
FETAL ASSESSMENT BY AMNIOCENTESIS
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Fetal antigen status can be inferred from information gained from 
antigen testing of the father. When necessary, fetal antigen status can be 
determined directly by cord-blood sampling or from fetal cells obtained 
by  amniocentesis.  Fetal  anemia  can  be  diagnosed  from  fetal  blood 
obtained  from  cord-blood  sampling.  In  general,  in  a  first  affected 
pregnancy,  hydrops  fetalis  is  unlikely  before  26  to  28  weeks,  and 
therefore invasive procedures to assess the degree of fetal  anemia can 
usually be delayed until that time. In patients who have previously had a 
severely affected fetus, fetal testing is usually started 1 to 4 weeks before 
the  time  the  fetus  was  noted  to  be  severely  affected  in  the  previous 
pregnancy.
Traditionally,  amniocentesis  with  analysis  of  amniotic  fluid  for 
breakdown  products  of  hemoglobin  has  been  used  to  identify  fetuses 
likely to be severely anemic.  In addition, fetal  blood sampling can be 
used to assess the fetal antigen status and degree of anemia in affected 
pregnancies.
ULTRASOUND
Ultrasound  evaluation  of  the  fetus  is  a  noninvasive  method  of 
evaluating the fetus at risk for significant anemia and hydrops. Hydrops is 
relatively easy to identify by ultrasound. Increased amniotic fluid volume, 
placental  thickening,  and  hepatosplenomegaly  are  ultrasound  signs  of 
early hydrops.
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DOPPLER STUDIES 
Recently, a number of studies have demonstrated that the degree of 
fetal anemia can be accurately predicted by Doppler studies of blood flow 
in the fetal middle cerebral artery (MCA). It  appears likely that MCA 
Doppler  will  replace  the  other  more  traditional  methods  of  fetal 
assessment  because  it  is  noninvasive,  widely  available,  easy  to  repeat 
regularly,  and well-accepted by the mothers47,  48,  49 Animal and human 
studies have demonstrated that blood flow in the brain is  increased in 
fetuses with anemia because of an increase in cardiac output and decrease 
in blood viscosity50, 51 
The MCA is identified using color flow Doppler ultrasound, and 
duplex  Doppler  is  then  used  to  estimate  the  peak  systolic  velocity. 
Normal  values  for  peak  systolic  velocity  in  the  MCA  have  been 
established for fetuses between 18 and 36 weeks of gestation.  Fetuses 
with peak systolic velocity <1.5 multiples of the median are at low risk 
for  significant  anemia  48.Fetuses  with  middle  cerebral  artery  Doppler 
estimated velocity >1.5 multiples of the median are considered at risk for 
severe anemia and further investigated by either fetal blood sampling or 
amniotic fluid bilirubin studies. MCA Doppler studies pose no risk to the 
pregnancy, and serial testing (every 2 to 4 weeks) is typically begun at 20 
to 24 weeks.
LILEY GRAPH
In 1961 Liley 52 described a method of amniocentesis and amniotic 
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fluid spectrophotometric analysis for predicting hemolytic disease.
The optical density reading at 450 nm (OD450) is directly related to 
the severity of hemolytic disease.  By plotting OD450 versus gestational 
age, Liley was able to evaluate the degree of hemolytic disease in 101 
Rh-immunised  pregnancies.  This  initial  work  performed  on  gestations 
after  28 weeks  allowed prediction  of  the clinical  course  based on the 
arbitrary  division  of  the  patients  into  three  zones.  Severe  hemolytic 
disease, fetal hydrops, and fetal death were temporally related to readings 
in the upper zone (zone 3). Mild or no hemolytic disease was correlated 
with zone 1. Empirical data and developing prognostic accuracies have 
evolved the graph to its current form. The method of measurement used, 
however, seems less important than the judgment and experience of the 
person reviewing the amniotic fluid results.
FETAL TO MATERNAL HEMORRHAGE ESTIMATION
The presence of fetal red cells in the maternal circulation may be 
identified by use of the acid elution principle first described by Kleihauer, 
Brown, and Betke, or any of several modifications. This test is based on 
the  fact  that  fetal  erythrocytes  contain  hemoglobin  F,  which  is  more 
resistant to acid elution than hemoglobin A. After exposure to acid, only 
fetal hemoglobin remains. Fetal red cells can then be identified by uptake 
of a special stain and quantified on a peripheral smear.
SCREENING OF NEWBORNS
Post natal screening of infants at  risk is by cord blood analysis, 
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serum bilirubin monitoring, non invasive bilirubin monitoring and end 
tidal carbon monoxide monitoring.
CORD BLOOD ANALYSIS
Decreased hemoglobin concentration, increased reticulocyte count, 
and increased numbers of nucleated erythrocytes in the peripheral blood 
reflect the presence of the hemolytic process. Hemoglobin determination 
performed on venous samples most accurately reflects the severity of the 
hemolytic process. Values less than 13 g/dL in the cord blood should be 
regarded as abnormal. 
The reticulocyte count is usually greater than 6% and may reach 
30% to  40%.  In  the  peripheral  blood,  nucleated  erythrocytes  may  be 
observed in addition to some degree of polychromasia and anisocytosis. 
A baby born to an Rh-negative mother (and Rh-positive father) should 
have  Rh  typing  and  a  Direct  Coomb’s  test  (DCT)  on  cord  blood. 
Newborns suspected to have Rh isoimmunisation should have a blood 
group and Rh typing, Direct Coombs Test, PCV and serum bilirubin on 
cord blood to facilitate early treatment. It has been suggested that cord 
hemoglobin less than 11.0 g/dL or a cord bilirubin higher than 4.5 mg/dL 
is  an  indication  for  an  immediate  exchange  transfusion  30.  Intensive 
phototherapy should be started at birth and continued till a level, which is 
5  mg/dl  less  than  that  for  exchange  blood  transfusion.  Prophylactic 
phototherapy may be beneficial and is indicated when the cord bilirubin 
is at least 4 mg/dl 53.
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As there is very little anti-A or anti-B antibody on the neonatal red 
blood cell in  ABO hemolytic disease, the cord blood direct antiglobulin 
test in this condition is only weakly positive and may be negative unless a 
sensitive  test  is  used.  One  currently  accepted  method in  hospital 
laboratories for performing the direct antiglobulin test is a gel test that is 
more  sensitive  than  formerly  used  techniques  for  detecting 
immunoglobulin G coating of newborn red cells. 
At birth the ABO hemolytic disease can be suspected by examining 
the cord blood for elevation of serum bilirubin, presence of maternal IgG 
anti  A  or  anti  B  antibodies  in  an  antibody-dependant  cell  mediated 
cytotoxicity (ADCC) assay and detection of antigen density of A or B 
antigens  on  the  red  blood  cells.  Reticulocytosis,  spherocytosis  and 
increased osmotic fragility of RBCs may be present.  The diagnosis of 
ABO hemolytic disease is supported by the finding of increased numbers 
of  spherocytes;  these  are  best  detected  by  evaluating  the  three-
dimensional shape of the erythrocyte. Increased erythrocyte production is 
also demonstrated by an increased reticulocyte count. 
The levels of IgG anti-A or anti-B in the mothers of babies with 
ABO  hemolytic  disease  is  significantly  higher  than  those  in  mothers 
whose infants do not have the disease. These tests are often not available 
and,  unfortunately,  are  not  high  in  specificity  or  sensitivity  in  the 
diagnosis  of  ABO  hemolytic  disease. The  nucleated  RBC  count  is 
elevated and falsely  elevates  the leukocyte  count,  reflecting a  state  of 
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erythropoiesis.  Spherocytosis  (<40%)  is  more  commonly  observed  in 
cases of ABO incompatibility. In severe hemolytic disease, schistocytes 
and  burr  cells  may  be  observed,  reflecting  ongoing  disseminated 
intravascular coagulation. A low reticulocyte count is observed in fetuses 
provided  with  intravascular  transfusion  in  utero  and  with  Kell 
alloimmunisation.
Neutropenia seems to be secondary to stimulation of erythropoiesis 
in favor of myelopoiesis
SERUM BILIRUBIN MONITORING 
Vinod  K.  Bhutani,  Ron  Keren,  MD,  et  al  54,  Department  of 
Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, 
suggested the hour-specific total serum bilirubin before discharge as the 
most accurate method for assessing risk of severe hyperbilirubinemia. A 
serum bilirubin measurement and the use of the critical bilirubin levels of 
4  mg/dL and 6 mg/dL at  the sixth hour of  life  will  predict  nearly  all 
newborns who will  have significant  hyperbilirubinemia and those who 
will develop  severe  hemolytic  disease  of  the  newborn.  Non  invasive 
monitoring of serum bilirubin using trans cutaneous bilirubinometers is 
useful in screening of neonates at risk.
END TIDAL CARBONMONOXIDE MONITORING
The degradation of hemoglobin results in the equimolar formation 
of bilirubin and carbon monoxide. After formation, the carbon monoxide 
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binds  to  hemoglobin  within  circulating  red  blood  cells  forming 
carboxyhemoglobin.  The  carboxyhemoglobin  dissociates  in  the  lung 
releasing carbon monoxide into the exhaled breath. The concentration of 
carbon monoxide present in the alveoli of the lungs is directly related to 
the  concentration  of  carboxyhemoglobin  within  the  blood.  The 
measurement  of  blood  carboxyhemoglobin  or  the  rate  of  carbon 
monoxide excretion 55 correlates with hemolysis 56,57,58. 
MANAGEMENT OF PATHOLOGICAL HYPERBILIRUBINEMIA 
Before  treatment  is  initiated,  the  minimum  evaluation  should 
include the infant's age and postnatal course, a maternal and gestational 
history, physical examination of the infant, and determination of the total 
serum bilirubin level and the rate at which it is rising. Jaundice in a term 
newborn  fewer  than  24  hours  old  is  always  pathologic.  It  should  be 
investigated  thoroughly  and  treated  appropriately.  Conjugated 
hyperbilirubinemia is never physiologic, and it may indicate the presence 
of a potentially serious underlying disorder. If jaundice persists for more 
than two weeks in a formula-fed infant and more than three weeks in a 
breastfed infant, further evaluation is warranted.
Laboratory  studies  should  include  a  fractionated  bilirubin  level, 
thyroid studies, evaluations for metabolic disorders or hemolytic disease, 
and an assessment for intestinal obstruction for a selected case. 
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Depending  on  the  rate  at  which  the  bilirubin  level  rises,  a 
newborn's  risk  of  developing  significant  hyperbilirubinemia  can  be 
classified as low, intermediate, or high. 
AAP gives guidelines for phototherapy and exchange transfusion 
in hospitalized infants of 35 or more weeks' gestation 37. 
Hyperbilirubinemia can be treated in three ways: 
a. Exchange transfusion removes bilirubin mechanically 
b. Phototherapy converts bilirubin to products that can bypass the 
liver's conjugating system and be excreted in the bile or in the 
urine without further metabolism 
c. Pharmacologic agents that interfere with heme degradation and 
bilirubin production, accelerate the normal metabolic pathways 
for bilirubin clearance, or inhibit the enterohepatic circulation of 
bilirubin. 
Phototherapy  is  the  most  common  treatment  in  use  for 
hyperbilirubinemia;  exchange  transfusions  generally  are  reserved  for 
phototherapy  failures  59.  The  bilirubin  level  at  which  intervention  is 
necessary is still a contentious issue. Treatment guidelines must rely on 
relatively uncertain estimates of risks and benefits  and the recognition 
that using a single serum bilirubin level to predict long-term behavioral 
and developmental outcomes is not reliable and will lead to conflicting 
results 60.
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PHOTOTHERAPY 
Phototherapy was discovered rather serendipitously in England in 
the 1950s and now is arguably the most widespread therapy of any kind 
(excluding  prophylactic  treatments)  used  in  newborns.  The  main 
demonstrated  value  of  phototherapy  is  that  it  reduces  the  need  for 
exchange transfusion 61, 62.  
Phototherapy is effective because three reactions can occur when 
bilirubin is exposed to light, as follows: 
1. Photo oxidation 
2. Configurational isomerisation 
3. Structural isomerisation
Bilirubin  can  be  photo-oxidised  to  water-soluble,  colourless 
products that can be excreted in the urine. This is a slow process and is 
probably only a minor contributor to the elimination of bilirubin during 
phototherapy.
Configurational isomerisation is a very rapid process that changes 
some  of  the  predominant  4Z,  15Z  bilirubin  isomer  to  water-soluble 
isomers in which one or both of the intramolecular bonds are opened (E, 
Z; Z, E; or E, E). In human infants, the 4Z, 15E isomer predominates, and 
at equilibrium conditions, the isomer constitutes about 20% of circulating 
bilirubin  after  a  few  hours  of  phototherapy.  This  proportion  is  not 
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influenced  significantly  by  the  intensity  of  light.  Thus,  although 
configurational isomerisation is extremely rapid and accounts for the bulk 
of the photochemical outcomes, it probably plays only a minor role in 
lowering the serum bilirubin concentration because although it is formed 
fastest, the clearance of the light-generated 4Z, 15E isomer is very slow 
(T½ ~15 hours)61.
Structural isomerisation consists of intramolecular cyclisation, an 
irreversible process, resulting in the formation of lumirubin. This process 
is  enhanced by increasing  the intensity  of  light.  During  phototherapy, 
lumirubin may constitute 2-6% of the total serum bilirubin concentration, 
which  is  much  lower  than  the  concentration  of  the  configurational 
isomers that form about 20% of the total bilirubin. The photo isomers of 
bilirubin are excreted in bile and, to some extent, in urine 63.
The efficacy of phototherapy depends on several important factors. 
1. Spectrum of light emitted 
2. Irradiance of light source
3. Design of phototherapy unit
4. Surface area of infant exposed to the light
5. Distance of infant from light source
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Blue-green spectrum is most effective; at these wavelengths, light 
penetrates skin well and is absorbed maximally by bilirubin. Irradiance or 
energy output may be increased in a phototherapy unit by decreasing the 
distance to within 15-20 cm of the infant. The ideal configuration is four 
special  blue  bulbs  (F20T12/BB)  placed  centrally,  with  two  daylight 
fluorescent  tubes  on  either  side.  The  power  output  of  the  lights 
(irradiance) is directly related to the distance between the lights and the 
newborn.  To expose the greatest  surface area, the newborn should be 
naked except for eye shields. Double surface phototherapy may be more 
effective than single surface phototherapy 64. 
The only contraindication to the use of phototherapy is conjugated 
hyperbilirubinemia,  as  occurs  in  patients  with  cholestasis  and  hepatic 
disease.  In  this  setting,  phototherapy may cause a  dark grayish-brown 
discoloration of the skin (bronze baby syndrome) 65. Potential problems 
that  may  occur  with  phototherapy  include  burns,  retinal  damage, 
thermoregulatory  instability,  loose  stools,  dehydration,  skin  rash,  and 
tanning of the skin 66. Because phototherapy is continuous, treatment also 
involves significant separation of the infant and parents 67. 
With intensive phototherapy, the total serum bilirubin level should 
decline by 1 to 2 mg per dL (17 to 34 µmol per L) within four to six 
hours.  The bilirubin level may decline more slowly in breastfed infants 
(rate  of  2  to  3  mg  per  dL  per  day)  than  in  formula-fed  infants. 
Phototherapy usually can be discontinued when the total serum bilirubin 
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level is below 15 mg/dL. The average rebound elevation of bilirubin level 
after phototherapy is below 1 mg per dL. Therefore, hospital discharge of 
most  infants  does  not  have  to  be  delayed  to  monitor  for  rebound 
elevation. 
Continuous phototherapy is better than intermittent phototherapy. 
Phototherapy  should  be  interrupted  in  a  newborn  only  during  breast-
feeding  and  nappy  changes.  In  case  of  hemolytic  or  rapidly  rising 
bilirubin or when a conventional unit is not effective, use of intensive 
phototherapy is warranted. This can be achieved by placing the infant on 
bili-blanket  and  using  additional  overhead  phototherapy  units  with 
special  blue  lights  and  lowering  the  phototherapy  units  to  within  a 
distance of 15-20 cm. 
When  used  properly,  phototherapy  is  a  very  effective  and  safe 
method  of  lowering  the  serum  bilirubin  concentration.  Its  use  has 
drastically  decreased  the  need  for  exchange  transfusion  and  it  has 
probably  contributed to the virtual  disappearance of  kernicterus in the 
low-birth-weight infants.
EXCHANGE TRANSFUSION 
Exchange transfusion is the most rapid method for lowering serum 
bilirubin concentrations. This treatment is rarely needed when intensive 
phototherapy is effective 68.  The procedure removes partially hemolysed 
and antibody-coated erythrocytes and replaces them with uncoated donor 
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red  blood  cells  that  lack  the  sensitising  antigen.   During  exchange 
transfusion,  bilirubin  from the  extra  vascular  space  is  drawn  into  the 
plasma,  and  partial  equilibration  between  extra  vascular  and  plasma 
bilirubin occurs almost instantaneously 69. Thus, by the end of a double-
volume  exchange,  in  which  only  about  15%  of  the  circulating 
erythrocytes remain, the serum bilirubin is still 45% to 60% of the pre 
exchange level 69, 70. Immediately after the exchange, further equilibration 
takes place, which is completed within 30 minutes and produces the early 
rebound of plasma bilirubin to 60% to 80% of the pre exchange level 69.
In the presence of hemolytic disease, severe anemia, or a rapid rise 
in the total serum bilirubin level (greater than 1 mg per dL per hour in 
less than six hours), exchange transfusion is the recommended treatment. 
Exchange  transfusion  should  be  considered  in  a  newborn  with 
nonhemolytic  jaundice  if  intensive  phototherapy  fails  to  lower  the 
bilirubin level. 
Complications of exchange transfusion can include air embolism, 
vasospasm,  infarction,  infection,  and  even  death 60.  Because  of  the 
potential  seriousness  of  these  complications,  intensive  phototherapy 
efforts should be exhausted before exchange transfusion is initiated.
PHARMACOLOGICAL TREATMENT
Phenobarbitone: Phenobarbital is a potent inducer of microsomal 
enzymes that increases bilirubin conjugation and excretion and increases 
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bile flow. When given in sufficient doses to the mother, the infant,  or 
both, Phenobarbital is effective in lowering serum bilirubin levels in the 
first week of life 71, 72. However, concerns about long-term toxicity when 
given to pregnant women militate against its use for this purpose 73. When 
used prophylactically in a dose of 5 mg/kg for 3-5 days after birth, it has 
shown  to  be  effective  in  babies  with  hemolytic  disease,  extravasated 
blood and in preterms without any significant side effects.
Intravenous  Immunoglobulins  (IVIG):  Controlled  trials  have 
confirmed that the administration of IVIG to infants with Rh hemolytic 
disease will significantly reduce the need for exchange transfusion  74. It 
also is likely that IVIG will help to mitigate the course of severe ABO 
hemolytic disease 75 and other isoimmune causes of hemolysis. The doses 
used have ranged from 500 mg/kg given over 2 hours soon after birth to 
800 mg/kg given daily for 3 days. In Rh hemolytic disease, anti-D-coated 
erythrocytes  are  removed  from  the  circulation  through  antibody-
dependent  lysis  by  cells  of  the  reticuloendothelial  system.  The 
mechanism of action of IVIG is unknown, but it is possible that it might 
alter  the  course  of  Rh  hemolytic  disease  by  blocking  Fc  receptors, 
thereby  inhibiting  hemolysis.  The  risks  of  IVIG therapy  are  certainly 
lower than those of exchange transfusion. 
Metalloporphyrins:  Certain  synthetic  metalloporphyrins  are 
powerful  competitive  inhibitors  of  heme  oxygenase  and  suppress  the 
formation of bilirubin. The inhibition of heme degradation to bilirubin 
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does  not  result  in  the  accumulation  of  heme;  the  heme  is  excreted 
unchanged in  the bile  in  quantities  that  compensate  for  the  decreased 
excretion  of  bilirubin  72. These  compounds  are  still  experimental  but 
showing  promise  in  various  hemolytic  and  non-hemolytic  settings 
without significant side effects.
FOLLOW-UP
Babies  with  serum bilirubin  >20  mg/dL  and  those  who  require 
exchange transfusion should kept under follow-up in the high- risk clinic 
for  neuro-developmental  outcome. Hearing assessment  (BERA) should 
be done at 3 months of corrected age.
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REVIEW OF LITERATURE
ABO  incompatibility  is  a  major  cause  of  neonatal 
hyperbilirubinemia  and  neonatal  hyperbilirubinemia  if  untreated  is 
associated with significant morbidity and mortality. So it is important to 
screen these at risk infants. Various studies have been undertaken in an 
effort  to  identify  an  effective  predictor  of  future  neonatal 
hyperbilirubinemia  in  babies  at  risk  of  ABO  incompatibility.  These 
studies are discussed in following paragraphs.
The exact incidence of ABO hemolytic disease is not known. The 
incidence in various studies range from 3.7% (Han P, Kiruba R, etal 73 ) to 
32.95 % (Chen JY, Ling UP et al 74 ). This marked difference may be due 
to racial variation, inter laboratory variation in bilirubin estimation or due 
to the criteria adopted for diagnosing ABO hemolytic disease.
Various  parameters  in  the  cord  blood  studied  for  prediction  of 
pathological  hyperbilirubinemia  in  ABO  incompatibility  include  cord 
blood bilirubin, cord blood reticulocyte count, direct coomb’s test, cord 
blood hemoglobin, end tidal carbon monoxide estimation etc.
J. Maxwell  Johnstone  75,  analysed cord blood samples of 1459 
babies born in West  Middlesex Hospital  and found out  that  the mean 
serum bilirubin values in  cord blood samples were 1.27 mg /dL.  The 
mean  cord  blood  bilirubin  values  of  ABO  heterospecific  pregnancies 
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(1.36 mg/dL) was found to be significantly higher than the homospecific 
pregnancies (1.24 mg/dL).
Procianoy RS et al. 76 from Brazil assessed the usefulness of direct 
Coombs test  in  diagnosing ABO-hemolytic  disease of  the newborn in 
132 term, AGA neonates. His study suggested that bilirubin concentration 
in the cord blood  > 4 mg/dL is useful for an early diagnosis of ABO-
hemolytic disease. In a study conducted by  Whyte J,  Graham H 77 on 
seventy-one  ABO  incompatible  infants  concluded  that  cord  serum 
bilirubin concentration had some predictive value, particularly when the 
level exceeded 85 micro mol/l, but it was a less reliable indicator and had 
greater value if used in association with the direct anti globulin test.. 
Chen JY, Ling UP et al 74 conducted a study in Taiwan in eighty-
eight healthy full-term newborn infants born to blood group O mothers 
and concluded that  maternal  IgG anti-A or  anti-B titers  > 512X, cord 
bilirubin levels  > 4 mg/dL or  positive direct  Coombs'  test  of the cord 
blood represent a "high risk" category, and should be placed in hospital 
where frequent re-evaluation and appropriate therapy are available.
Levine DH,  Meyer HB 78 analysed 1391 cord blood specimens 
and found out that cord blood bilirubin  was not diagnostic of hemolytic 
disease  but  was  moderately  predictive  of  peak  bilirubin  levels.  Study 
conducted by Han P, Kiruba R, etal 73, National University of Singapore 
on 1608 babies also suggested that cord bilirubin was of low predictive 
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value for severe hemolytic disease due to ABO incompatibility.  These 
data support the notion that it  is  not cost effective to screen for  ABO 
incompatibility.
Vinod  K.  Bhutani, Ron  Keren,  MD,  et  al  54,  Department  of 
Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, 
suggested that the hour-specific total serum bilirubin before discharge has 
been shown to be the most accurate method for assessing risk of severe 
hyperbilirubinemia. Transcutaneous  bilirubin  and  end-tidal  carbon 
monoxide measurements  and screening for  specific  genetic markers of 
neonatal hyperbilirubinemia have the potential to refine risk assessment 
strategies further. 
Knupfer M, Pulzer F et al 79 investigated the predictive value of 
umbilical cord serum bilirubin for the postnatal course of bilirubinaemia 
in healthy term and near-term newborns and found out that umbilical cord 
serum  bilirubin  values  correlated  with  the  development  of 
hyperbilirubinemia and phototherapy requirement. They concluded that a 
cut  off  value of  30  micromol/litre  of  cord bilirubin can  be  useful  for 
predicting phototherapy requirement.
Various studies assessed the usefulness of direct coomb’s test in 
babies with ABO incompatibility. The usefulness of direct coombs test in 
predicting significant hyperbilirubinemia is controversial. But most of the 
studies prove that even though coomb’s test  may be negative in ABO 
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hemolytic disease coomb’s test if positive may indicate a risk of severe 
hemolysis.
Study conducted by   Dufour DR,  Monoghan WP etal  80 in 254 
babies with ABO hemolytic disease found out that sixty-five per cent of 
the  infants  who  had  positive  direct  antiglobulin  tests  experienced 
jaundice, compared with approximately 35% of control infants or infants 
who had ABO hemolytic  disease  of  the newborn with negative direct 
antiglobulin test results. Infants who had ABO hemolytic disease of the 
newborn  with  positive  direct  antiglobulin  test  results  also  had greater 
severity  of  jaundice  than  control  infants  or  infants  who  had  ABO 
hemolytic disease of the newborn with negative direct antiglobulin test 
results.  Marcello  Orzalesi  M.D.,  Fulvia  Gloria  Math.D  etal 81 
Department of Pediatrics,  Yale  University School of  Medicine,  Rome, 
Italy studied newborn infants incompatible with their mothers in the ABO 
system and found out  that  there  is  a  potentially  higher risk  of  severe 
hyperbilirubinemia  particularly  in  the  presence of  a  positive  direct 
Coombs test. 
Study conducted by Whyte J, Graham H 77 on seventy-one ABO 
incompatible  infants  concluded that  modified Direct  Antiglobulin  Test 
(spin  DAGT)  was  positive  in  all  infants  who  required  treatment  for 
hemolytic jaundice and only DAGT positive children showed evidence of 
impending hemolytic anaemia. The elution test, which is frequently used 
as a diagnostic tool in ABO hemolytic disease, had no predictive value 
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and they  felt  that  its  putative  value  is  due  to  over-diagnosis  of  ABO 
hemolytic  disease. Chen JY,  Ling  UP et  al  74  conducted  a  study  in 
Taiwan in eighty-eight healthy full-term newborn infants born to blood 
group O mothers and concluded that ABO incompatible newborn infants 
with positive direct Coombs' test of the cord blood represent a "high risk" 
category, and should be placed in hospital where frequent re-evaluation 
and appropriate therapy are available. 
Procianoy RS et al. 76 from Brazil assessed the usefulness direct 
Coombs test  in  diagnosing ABO-hemolytic  disease of  the newborn in 
132 term, AGA neonates. His study suggested that the direct Coombs test 
in combination with quantitative elution test and bilirubin concentration 
in  the  cord  blood  is  useful  for  an  early  diagnosis  of  ABO-hemolytic 
disease.
Bel omos J et al, Barcelona 82.studied the ABO hemolytic disease 
of the newborn and found out that direct antiglobulin test was positive in 
11.3% of them. The Elution was positive in all the newborns with direct 
antiglobulin test positive. They concluded that the direct antiglobulin test 
is  very  useful  to  detect  the  newborns  liable  to  get  serious  jaundice.
Levine DH, Meyer HB 78 analysed 1391 cord blood specimens for type, 
Rh,  direct  antiglobulin  test,  indirect  Coombs,  and  total  and  indirect 
bilirubin.  They  found  out  that  direct  antiglobulin  test  was  neither 
diagnostic nor predictive of severity. They concluded that the data does 
not support the use of any routine screening tests in the management of 
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ABO hemolytic disease.
Han  P,  Kiruba  R,  etal  73,  National  University  of  Singapore 
conducted a study on 1608 babies. The baby-maternal pairs were typed 
for  ABO,  Rh,  and  tested  for  direct  Coombs'  test,  maternal  titer,  cord 
blood bilirubin and haptoglobin levels. They found out that the incidence 
of hemolytic disease due to ABO incompatibility was 3.7% of all group 
O  mothers.  Coombs'  test,  maternal  antibody  titre,  cord  bilirubin  and 
haptoglobin  levels  were  of  low predictive  value  for  severe  hemolytic 
disease due to ABO incompatibility. The data further support the notion 
that it is not cost effective to screen for ABO incompatibility
Dinesh D 83,  New Zealand Blood Service, estimated the positive 
predictive  value  of  a  positive  direct  antiglobulin  test  for  hemolytic 
disease  is  23%.  The  sensitivity  was  estimated  to  be  86%. 
Recommendations for testing are discussed but remain controversial in 
practice. 
Marguerite  Herschel,  MD et  al 84 studied  babies  with  risk  of 
ABO incompatibility and compared those who are direct antiglobulin test 
positive with the negative ones and found out that  in direct antiglobulin 
test-negative  newborns  with  significant  jaundice or  increased  bilirubin 
production,  even  if  ABO-incompatible, a  cause  other  than 
isoimmunisation should be sought. 
Molly Ann Katz, MD, William p. Kanto Jr. M.D et al 85 Medical 
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College of Georgia, Augusta studied 230 neonates with ABO hemolytic 
disease  (HD)  and  concluded  that  there  is  no  significant  difference in 
clinical severity between AO-HD and BO-HD as measured by number of 
neonates  with  hyperbilirubinemia  and/or  those requiring  exchange 
transfusion;  hemoglobin  concentration; reticulocyte  count;  bilirubin 
concentration; and incidence of anemia after discharge from the hospital.
S.  Umit  Sarici,  MD  86 Turkey  found  out  that  a  positive  direct 
antiglobulin test, along with reticulocyte count and serum bilirubin is a 
good predictor for the development of significant hyperbilirubinemia and 
severe hemolytic disease of the newborn in ABO incompatibility.
Most  of  the  studies  done  across  the  world  concluded  that  cord 
blood  analysis  is  useful  for  screening  babies  at  risk  of  ABO 
incompatibility  for  pathological  hyperbilirubinemia.  Studies  conducted 
by Levine DH, Meyer HB 78 and Han P, Kiruba R, etal 73 found out that 
routine screening of cord blood is not useful and cost effective. Direct 
coomb’s  test  though  has  a  low  sensitivity,  is  useful  in  predicting 
pathological hyperbilirubinemia in most of studies80, 85, 76, 82, 86. Low cord 
hemoglobin levels and reticulocytosis was used a predictor of significant 
hemolysis and severity of ABO hemolytic disease rather than a screening 
test.
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JUSTIFICATION OF STUDY
The earlier studies have been undertaken in an effort  to identify 
early predictors of neonatal hyperbilirubinemia. In Tamilnadu nearly than 
80% of the deliveries take place in hospitals. The trend in these hospitals 
is  early discharge of mother  and infant in 24-72hrs unless mother  has 
undergone caesarean section or puerperal sterilization. Very few come for 
follow up and there is no proper home visit  by field health worker to 
these mothers and infants.
The common reason for readmission of newborn in early neonatal 
period is jaundice.  Another important fact to be considered is that the 
peak serum bilirubin is attained on the 3rd or 4th day of life in a term 
infants.  This  may  lead  to  development  of  bilirubin  encephalopathy  at 
home. By the time these infants are brought to the neonatal care unit, they 
might  have  crossed  the  stage  of  salvation  which  leads  to  increased 
morbidity and mortality. From this it is evident that a prediction for the 
development of pathological jaundice is highly essential to decrease the 
morbidity and mortality due to bilirubin encephalopathy. A large majority 
of  babies  admitted  with  neonatal  hyperbilirubinemia  will  have  ABO 
incompatibility.  It  may  not  be  feasible  to  screen  all  infants  born  for 
neonatal hyperbilirubinemia. But screening of babies who are at risk of 
developing hyperbilirubinemia due to ABO incompatibility is justifiable. 
Most  studies  done  in  our  country  aims  at  prediction  of  ABO-
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hemolytic disease by cord bilirubin alone. Cord bilirubin alone is a poor 
predictor  of  ABO-hemolytic  disease.  A combination of  cord bilirubin, 
direct  coomb’s test,  reticulocyte  count,  cord hemoglobin may act  as a 
very good predictor of ABO-hemolytic disease. A baby may be safely 
discharged  at  48+/-hrs  when  all  the  above  tests  are  negative  thus 
decreasing the hospital  stay  if  study proves it  effective.  Thus  there  is 
economic benefit and decreases risk of nosocomial infection in newborn 
and mother.  If cord blood values prove to be useful in predicting ABO-
hemolytic  disease,  it  will  be  an  early  non invasive  screening method. 
Early  diagnosis  of  ABO-hemolytic  disease  is  useful  in  peripheral 
hospitals where phototherapy units are not available.
Various  studies  conducted  across  the  world  have  showed  the 
critical  cord  serum  bilirubin  levels  for  development  of  pathological 
hyperbilirubinemia around 1.7 mg % to 5 mg%  74  –  88. It was therefore 
proposed to find out the level of cord bilirubin in our setup beyond which 
our  infants  are  at  increased  risk  of  developing  pathological 
hyperbilirubinemia. Usefulness of other cord blood tests like reticulocyte 
count, cord blood hemoglobin and direct coomb’s test are debatable.
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OBJECTIVES OF THE STUDY
To study:
A. Whether cord blood analysis (cord bilirubin, reticulocyte count, hemoglobin 
and direct coomb’s test) can serve as a useful predictor in a newborn at risk of 
ABO incompatibility for developing pathological hyperbilirubinemia.
B. Appropriate level of cord bilirubin, hemoglobin and reticulocyte count which 
can pick up maximum number of newborns who would go for pathological 
hyperbilirubinemia.
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SUBJECTS AND METHODS
a) STUDY DESIGN: Descriptive study
b) STUDY PERIOD: 18 months (from January 2006 to June 2007)
c) STUDY POPULATION:
Babies born of caesarean section to O positive mothers during the 
period from January 2006 to June 2007 in the Institute of Obstetrics and 
Gynaecology  were  randomly  selected  for  the  study.  Babies  born  of 
caesarean section were included in the study because these babies were 
usually  kept  in  the  hospital  for  a  period  of  10  days  and they  can  be 
followed up during that period for the presence of jaundice.
d) OUTCOME MEASURES:
Serum  bilirubin  taken  in  the  4th day  is  taken  as  the  outcome 
measure. Avery gives the criteria for pathological jaundice 1 as 
 Jaundice within 24hours of life.
 Jaundice persisting >1 week.
 Total  serum bilirubin  more  than  the  95th percentile  for  the  age  in 
hours.
 Direct bilirubin >1.5 mg/dl.
 Total  serum  bilirubin  increasing  more  than  5  mg/dl/day  or  0.5 
mg/dl/hour. 
In our study pathological hyperbilirubinemia is defined as a serum 
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total  bilirubin  level  >15  mg/dL on  4th day  of  life  or  any  total  serum 
bilirubin more than the 95th percentile for the age in hours taken 37. See 
figure below.
Figure: Nomogram for designation of risk in 2840 well newborns 
at 36 or more weeks’ gestational age with birth weight of 2000 g or more 
or 35 or more weeks’ gestational age and birth weight of 2500 g or more 
based on the hour-specific serum bilirubin values. Bhutani et al 37.
e) SAMPLE SIZE
Sample  size  was  calculated  based  on  incidence  of  pathological 
bilirubinaemia  in  ABO  incompatibility  in  our  neonatal  set  up.  For 
correlation of 0.6, alpha error of 0.01and beta error of 0.01 the sample 
size was calculated to be 127. A total of 136 cases with incompatible 
blood group were studied.
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1. INCLUSION CRITERIA
1) A+ve or B +ve babies born to O+ve mothers.
2) New born of GA > 37 wks
3) New born of  B.wt > 2.5 kg and < 4kg
4) Mothers  undergoing  LSCS  for  indications  not  causing 
hyperbilirubinemia in new born
5) Apgar >7 in newborn
a. EXCLUSION CRITERIA
2. Neonatal  problems  causing  hyperbilirubinemia  like  birth 
asphyxia, sepsis, birth trauma, congenital malformation, etc.
3. Significant  diseases  in  mother,  which  can  cause 
hyperbilirubinemia in newborn, like GDM.
f) MANOEUVRE
The  study  was  conducted  in  the  Institute  of  Obstetrics  and 
Gynaecology, Egmore. 212 babies born of caesarean section fulfilling the 
criteria were randomly recruited for the study. After initial stabilization of 
baby  3  mililitres  of  cord  blood  was  collected  in  3  separate  prepared 
bottles and sent to the Institute Of Child Health immediately for blood 
grouping,  direct  coomb’s  test,  serum  bilirubin,  hemoglobin,  and 
reticulocyte count estimation. 
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Mean while a thorough history was taken with special emphasis on 
those  condition  leading  on  to  pathological  hyperbilirubinemia.  In 
neonatal  history  any  neonatal  complications  were  asked  including  the 
history of passage of meconium within 24 hours. Baby’s birth weight, a 
detailed general examination to rule out congenital anomalies, presence 
of concealed hemorrhage like hematomas or ecchymosis, breast feeding 
history were obtained. All babies who develop any other risk factor other 
than ABO incompatibility were excluded from the study.
Of  the  212  babies  screened,  136  babies  were  at  risk  of  ABO 
incompatibility (A or B group babies delivered to O positive mothers). 
The rest of the babies were O group. All the babies who were A or B 
positive were followed up daily for clinical jaundice. Serum bilirubin was 
repeated  on  the  fourth  day.  If  the  baby  developed  significant  clinical 
jaundice  before  the  4th day  then  serum  bilirubin  was  estimated  and 
appropriate treatment was started if required.
SERUM BILIRUBIN ESTIMATION
Bilirubin in our biochemistry department was estimated by Diazo 
method. Reagents used are absolute methanol, hydrochloric acid, diazo 
reagent and standard solution of bilirubin. Serum was diluted with water 
and methanol was added in an amount insufficient to precipitate proteins, 
yet sufficient to ensure that all the bilirubin reacts with the diazo reagent. 
Bilirubin reacts with diazotized sulphanilic acid to produce azo bilirubin 
which was quantified by spectrophotometry.
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RETICULOCYTE COUNT
Reticulocyte  count  was  estimated  by  supravital  staining  with 
brilliant  cresyl  blue.  Blood  was  mixed  with  brilliant  cresyl  blue  and 
peripheral smear was examined for polychromatic RBCs.
HEMOGLOBIN ESTIMATION
Hemoglobin estimation in this study was done with the help of auto 
analyzer.
DIRECT COOMB’S TEST
Blood was collected in EDTA bottle. One drop of 2.5% suspension 
of red cells was placed on a clean labeled test tube. The red cells were 
washed 3-4 times with saline. Add 1-2 drops of AHG reagent. Mix and 
centrifuge  at  1000 rpm for  1  minute.  The  tube  was  gently  shaken  to 
dislodge the cell button and read the results using a concave mirror. If the 
results were negative, the test tube was incubated for further 5 minutes at 
room temperature, centrifuged and looked for results. 1 drop of 5% IgG 
sensitized  red  cells  were  added  to  the  negative  tests.  Look  for 
agglutination, if a negative test was obtained the test result was invalid 
and has to be repeated.
Agglutination  of  red  cells  was  a  positive  direct  coomb’s  test. 
Control tubes should be read before final interpretation. An immediate 
positive reaction indicates presence of IgG coating antibodies. Reaction 
due to IgG becomes weaker after incubation. A positive reaction after 5 
minutes indicates coating by complement components. 
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RESULTS
A total of 136 babies with the risk of ABO incompatibility were 
included in the study. 73% (99) of the babies developed clinical jaundice 
and nearly 10% (13) of cases developed pathological jaundice.
The data obtained was analysed as follows:
1. features  of  study  population  (sex,  birth  weight,  blood  group 
distribution)
2. Correlation of cord blood bilirubin with peak bilirubin values.
3. Receiver operated characteristic curve for cord bilirubin and cut off 
value for predicting pathological hyperbilirubinemia.
4. Correlation of cord blood hemoglobin with peak bilirubin values. 
5. Receiver operated characteristic curve for cord hemoglobin and cut off 
value for predicting pathological hyperbilirubinemia.
6. Correlation  of  cord  blood  reticulocyte  count  with  peak  bilirubin 
values.
7. Cut  off  value  of  cord  blood  reticulocyte  count  for  predicting 
pathological hyperbilirubinemia.
8. Correlation  between  direct  coombs’  test  and  pathological 
hyperbilirubinemia.
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Physiological Jaundice 
Pathological hyperbilirubinemia 
No jaundice 
Figure 1: Incidence of jaundice and pathological hyperbilirubinemia
Out  of  the  136  babies  who  were  at  risk  of  ABO 
incompatibility, 73% (99) of the babies developed clinical jaundice and 
nearly 10% (13) of cases developed pathological jaundice.
SEX DISTRIBUTION
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73
54%
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63
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Figure 2: sex distribution in study population
Out of the 136 babies studied 73 were males (54%) and 63 were 
females (46%).
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Figure 3: sex distribution in babies who developed clinical jaundice 
and pathological hyperbilirubinemia
The  incidence  of  clinical  jaundice  and  pathological 
hyperbilirubinemia was not significantly different in both sexes (P=0.92).
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WEIGHT DISTRIBUTION
In our study group only babies between 2.5 to 4 kilograms were 
included (Appropriate for Gestational age)
Wt No Jaundice Jaundice Pathological 
hyperbilirubinemia
2.5-3 26 60 8
3-3.5 10 35 4
3.5-4 1 4 1
0%
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30%
40%
50%
60%
70%
80%
90%
100%
No Jaundice Jaundice Pathological
hyperbilirubinemia
3.5-4
3-3.5 
2.5-3
Figure 3: weight distribution
No  significant  difference  in  incidence  of  clinical  jaundice  or 
pathological  hyperbilirubinemia  was  found  between  various  weight 
groups (p value 0.54)
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BLOOD GROUP AS A RISK FACTOR
Out of the 136 babies, 66 were A group (62 A positives and 4 A 
negatives)  and  70  were  B  group  (69  B  positives  and  1  B  negative). 
Incidence of clinical jaundice B group (85%) was higher in compared to 
A group (74%). But  this  difference was not  statistically  significant  (p 
value 0.91). No significant difference was there between the incidence of 
pathological hyperbilirubinemia also.
Blood group No Jaundice Jaundice Pathological 
hyperbilirubinemia
A+ 18 44 6
A- 2 2 0
B+ 16 53 7
B- 1 0 0
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CORRELATION  BETWEEN  CORD  BILIRUBIN  AND  4TH DAY 
BILIRUBIN
Cord bilirubin
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Figure 4: Correlation between cord bilirubin and 4th day bilirubin
Cord bilirubin has excellent correlation with the 4th day bilirubin 
levels. Pearson’s correlation, r = 0.86 (p-value < 0.001). 
For  who  were  started  on  phototherapy  before  the  4th day,  a 
corresponding 4th day value based on nomagram was used for statistical 
analysis. 
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PREDICTIVE VALUE OF CORD BILIRUBIN LEVELS
Cord bilirubin (mg%) Sensitivity Specificity
>.8 100.00% 0.00%
>1 100.00% 24.39%
> 1.1 100.00% 35.77%
>1.2 100.00% 42.28%
>1.4 100.00% 53.66%
>1.5 100.00% 57.72%
>1.6 100.00% 60.16%
>1.7 100.00% 71.54%
>1.8 100.00% 73.17%
>2 100.00% 76.42%
>2.1 100.00% 78.05%
>2.2 100.00% 81.30%
>2.3 100.00% 85.37%
>2.4 100.00% 88.62%
>2.6 100.00% 91.06%
>2.8 92.31% 93.50%
>2.9 92.31% 96.75%
>3 92.31% 97.56%
>3.1 84.62% 97.56%
>3.2 84.62% 98.37%
>3.4 53.85% 99.19%
>3.6 46.15% 99.19%
>3.8 30.77% 100.00%
>4.1 15.38% 100.00%
>4.2 7.69% 100.00%
>4.2 0.00% 100.00%
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RECIEVER OPERATED CHARACTERISTIC CURVE 
Figure 5: ROC curve for cord bilirubin
Area  under  the  curve  is  0.9872  which  means  that  a  randomly 
selected child with hyperbilirubinemia has a score larger  than that  for 
randomly chosen child without hyperbilirubinemia 98% of the time.
A value  of  > 3  mg/dL can be  used  as  a  cut  off  for  predicting 
pathological hyperbilirubinemia with a specificity of 92.3%, sensitivity of 
97.5%, positive predictive value of 84.6 % and negative predictive value 
of 98.4 %
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CORD BLOOD HEMOGLOBIN AND 4TH DAY BILIRUBIN
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Figure 6: Correlation between cord hemoglobin and 4th day bilirubin
Lower  cord  hemoglobin  is  associated  with  higher  risk  of 
hyperbilirubinemia. The strength of the association is weak - Pearson’s 
correlation r = - 0.139 (p-value=0.11).
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PREDICTIVE VALUE OF CORD HEMOGLOBIN LEVELS 
Cord hemoglobin (g %) Sensitivity Specificity
11.2 .000 .000
12.35 .000 .024
12.6 .077 .033
12.95 .077 .041
13.4 .231 .057
13.75 .231 .065
14.05 .231 .073
14.25 .385 .081
14.4 .462 .081
14.55 .538 .293
14.9 .538 .301
15.3 .538 .309
15.45 .615 .496
15.95 .846 .805
16.5 .923 .976
16.95 1 .976
17.5 1 .984
17.95 1 .992
19.2 1 1
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RECIEVER OPERATED CHARACTERISTIC CURVE
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Figure 7: ROC curve for cord hemoglobin
Area under the curve was .633. A hemoglobin value below 14.55g/
dL can be used as a good predictor from this curve with a sensitivity of 
53.8 %, specificity of 70.7 % positive predictive value of 15.9 % and 
negative predictive value of 93.4 %
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CORRELATION BETWEEN RETICULOCYTE COUNT AND 4TH 
DAY BILIRUBIN
Retic count
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Figure 8: Correlation between cord reticulocyte count and 4th day 
bilirubin
The  risk  of  hyperbilirubinemia  increases  with  an  increase  in 
reticulocyte count p-value = 0.002. The strength of the correlation was 
weak Spearman’s correlation r = 0.364 (p-value <0.01). 
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Cord reticulocyte count (%) Sensitivity Specificity
> 1 1.00 .000
> 2 .462 .667
> 3 .308 .943
> 4 .077 1
> 5 .000 1
A reticulocyte count  >2% could predict  the risk of  pathological 
hyperbilirubinemia with a sensitivity of 46 % and specificity of 67%.
DIRECT COOMBS TEST AND PATHOLOGICAL HYPERBILIRUBINEMIA
Direct coomb’s test Pathological hyperbilirubinemia
Present Absent
Positive 2 0
Negative 11 123
Direct  coomb’s  test  was  positive  in  only  1.5  %  of  the  babies 
studied. It was positive in 15.4 % of babies who developed pathological 
hyperbilirubinemia.  All  children  who  had  positive  Direct  coombs  test 
developed pathological hyperbilirubinemia. P-value = 0.008
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DISCUSSION
The  major  cause  of  pathological  hyperbilirubinemia  is  ABO 
incompatibility  1. This study was conducted to find out whether routine 
cord  blood  analysis  can  be  useful  in  predicting  pathological 
hyperbilirubinemia  in  newborns  at  risk  of  pathological 
hyperbilirubinemia.  The  aim  was  to  find  out  whether  cord  blood 
bilirubin, hemoglobin and reticulocyte count values correlated with the 
peak bilirubin values. If these values could predict the development of 
pathological hyperbilirubinemia we could decide on the early discharge 
of these at risk babies. 
This  study  included  136  babies  who  were  at  risk  of  ABO 
incompatibility which include babies with either A or B blood group born 
to O positive mothers. All babies were term (>37 weeks) and appropriate 
for gestational age (2.5 – 4 kg). Those babies who had other potential 
causes for developing jaundice like birth asphyxia, sepsis, birth injuries, 
mother with diabetes, PIH were excluded from the study. Preterm babies 
were excluded from the study because the serum bilirubin levels and the 
peak level going for kernicterus were highly variable. The aim was to 
find  out  cord  blood  analysis  is  useful  in  predicting  pathological 
hyperbilirubinemia.
Factors in the cord blood that we studied included cord bilirubin, 
hemoglobin,  reticulocyte  count  and  direct  coomb’s  test.  Higher  cord 
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bilirubin levels, lower cord hemoglobin, higher reticulocyte count and a 
positive  direct  coomb’s  test  were associated with a  higher  risk  of  the 
babies to develop pathological hyperbilirubinemia. In our study we tried 
to determine the correlation between cord blood bilirubin, hemoglobin, 
reticulocyte  count  and  direct  coomb’s  test  positivity  with  the 
development  of  pathological  hyperbilirubinemia.  Final  outcome 
measurement is pathological bilirubinaemia which is defined in our study 
as a 4th day bilirubin value above 15 mg/dL or a serum bilirubin level 
more than the 95th percentile for the age in hours.
13 out of 136 babies studied in our study developed pathological 
hyperbilirubinemia in our study (9.56 %). Bilirubin peaking was mostly 
noted in the 3rd and 4th day. Out of the 13 babies who had pathological 
hyperbilirubinemia 12 required phototherapy (phototherapy started on 3rd 
or 4th day) and 1 required exchange transfusion (on 3rd day of life). The 
baby who required exchange transfusion had a cord blood bilirubin of 
4.2mg/dL, cord blood hemoglobin 13.2mg/dL. But her reticulocyte count 
was 1 % and direct coomb’s test was negative.
Cord bilirubin values in the study population were in the range of 
<1  to  4.2mg/dL,  while  that  in  the  babies  who  developed 
hyperbilirubinemia was in the range of 2 – 4.2 mg/dL. The mean bilirubin 
level  in  babies  with  pathological  hyperbilirubinemia  was  3.1  mg/dL, 
where as those who didn’t develop it was 1.31 mg/dL (p value <0.01).
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Cord hemoglobin values in the study population were in the range 
of  12.2  to  18.2  mg/dL,  while  that  in  the  babies  who  developed 
hyperbilirubinemia was in the range of 12.5 – 16.6 mg/dL. The mean 
hemoglobin  level  in  babies  with  pathological  hyperbilirubinemia  was 
14.73 mg/dL, where as those who didn’t develop it was 14.62 mg/dL (p 
value 0.92).  Hemoglobin was a poor predictor for the development of 
pathological hyperbilirubinemia.
Reticulocytosis in ABO hemolytic disease range from 6 % to 40 % 
in various studies 86, 85. Reticulocytosis is seen in cord blood itself as the 
hemolysis in ABO incompatibility starts in utero itself. But in our study 
significant reticulocytosis was seen in none of the babies.
Direct coomb’s test is usually negative or weakly positive in babies 
with babies with ABO incompatibility. In our study only two babies with 
pathological hyperbilirubinemia had Direct coombs test positivity (15.4 
%).  None  of  the  babies  without  pathological  hyperbilirubinemia  had 
Direct coombs test positive.
CORRELATION OF VARIOUS CORD BLOOD ANALYSIS WITH 
HYPERBILIRUBINEMIA
Previous  studies  conducted  showed  a  good  correlation  between 
cord  blood  bilirubin  and  the  development  of  pathological 
hyperbilirubinemia.  The  cord  bilirubin  values  which  can  predict 
pathological  hyperbilirubinemia  range  from  1.7  mg/dL  (Knupfer  M, 
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Pulzer F et al  79) to 5 mg/dL (Whyte J,  Graham H 77) in various studies. 
The correlation of hemoglobin and reticulocyte count is not well studied. 
Cord hemoglobin level below 11 mg/dL to 11.5 mg/dL is associated with 
significant  morbidity  and  mortality  in  babies  with  pathological 
hyperbilirubinemia1. 
In our study cord bilirubin has excellent correlation with the 4th day 
bilirubin levels Pearson’s correlation, r = 0.86 (p-value < 0.001). So cord 
bilirubin  can  effectively  predict  the  risk  of  pathological 
hyperbilirubinemia.  This  results  are  similar  to  that  of  studies  done by 
Whyte J, Graham H 77Chen JY, Ling UP et al 74Procianoy RS et al. 76.
Lower  cord  hemoglobin  is  associated  with  higher  risk  of 
hyperbilirubinemia. The strength of the association is weak – Pearson’s 
correlation  r=  -  0.139  (p-value=0.11).  The  risk  of  hyperbilirubinemia 
increases  with  an  increase  in  reticulocyte  count p-value  =  0.002.  The 
strength of the correlation was weak Spearman’s correlation r= 0.364 (p-
value <0.01). But in our study the reticulocytosis in babies with ABO 
incompatibility  was  not  in  the  pathological  range  for  the  newborns. 
DIRECT  COOMBS  TEST  was  positive  in  only  1.5  % of  the  babies 
studied. It was positive in 15.4 % of babies who developed pathological 
hyperbilirubinemia. All children with positive DIRECT COOMBS TEST 
developed pathological hyperbilirubinemia. P-value = 0.008
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PREDICTIVE VALUE OF CORD BLOOD TESTS
A cord bilirubin value of  > 3mg/dL can be used as a cut off for 
predicting pathological hyperbilirubinemia with a specificity of 92.3%, 
sensitivity  of 97.5%, positive predictive value of 84.6 % and negative 
predictive value of 98.4%.
A hemoglobin  value  below 14.55  g/dL  can  be  used  as  a  good 
predictor from this curve with a sensitivity of 53.8 %, specificity of 70.7 
%, positive predictive value of 15.9 % and negative predictive value of 
93.4 %.
A reticulocyte count  >2% could predict  the risk of  pathological 
hyperbilirubinemia with a  sensitivity  of  46 % and specificity  of  67%. 
Direct  coomb’s  test  is  positive  in  15.4  %  of  babies  who  developed 
pathological hyperbilirubinemia. All children who had positive DIRECT 
COOMBS TEST developed pathological hyperbilirubinemia. (P-value = 
0.008)
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CONCLUSION
 Cord  blood  analysis  is  useful  for  predicting  pathological 
hyperbilirubinemia in babies at risk of ABO incompatibility.
 In  cord  blood  analysis  cord  bilirubin  is  the  best  predictor  for  the 
development of hyperbilirubinemia.
 Neonates with cord bilirubin values  > 3 mg/dL are at higher risk for 
developing pathological hyperbilirubinemia.
 A lower cord blood hemoglobin level is associated with a higher 4th 
day bilirubin level.
 A cord  hemoglobin  level  below 14.55 g/dL was associated  with  a 
higher risk of babies to develop pathological hyperbilirubinemia.
 Significant reticulocytosis in cord blood was not seen in babies with 
the risk of ABO incompatibility.
 Though Direct coomb’s test was positive only 15 % of babies with 
pathological  hyperbilirubinemia,  all  babies  with  positive  direct 
coomb’s test developed pathological hyperbilirubinemia.
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ANNEXURE
PROFORMA
Sl no:
Mothers name: Age: IP no. :
Baby’s blood group:
Details of mother:
LMP:
EDD:
Blood group: O+ve
Obstetric index:
Consanguinity:
H/o jaundice during pregnancy:
H/o GDM:
H/o PIH:
Fever/lymphadenopathy in antenatal period:
Addictions / drug intake:
Previous obstetric history:
Family history of jaundice / liver disease:
Previous history of neonatal jaundice:
If present intervention done:
Mode of delivery: normal / LSCS / Forceps
If LSCS, indication:
Induction of labour:
H/o foul smelling liquor/ maternal fever:
Examination of baby:
Apgar:
Maturity:
Birth weight:
Sex:
CVS:
RS:
P/A:
CNS:
Hematomas / ecchymosis:
Meconium passed – within 24 hours.
   Delayed beyond 24 hours.
Lab results:
Cord bilirubin - Total:
    Direct:
Cord direct coomb’s test:
Cord retic count:
Hemoglobin:
Bilirubin done on any subsequent day:
4th day bilirubin:
Clinical details of baby: 
Significant disease in early neonatal period:
Time of onset of clinical jaundice:
 Interventions done:
Phototherapy 
Exchange transfusion
